SPY445.87+3.37 0.76%
DIA352.85+3.84 1.10%
IXIC14,897.34+73.91 0.50%

BRIEF-Lynparza In Combination With Abiraterone Significantly Delayed Disease Progression In Propel Phase 3 Trial

reuters.com · 09/24/2021 07:35
BRIEF-Lynparza In Combination With Abiraterone Significantly Delayed Disease Progression In Propel Phase 3 Trial

- Merck & Co Inc MRK:

  • LYNPARZA® (OLAPARIB) IN COMBINATION WITH ABIRATERONE SIGNIFICANTLY DELAYED DISEASE PROGRESSION IN PATIENTS REGARDLESS OF BIOMARKER STATUS IN PROPEL PHASE 3 TRIAL IN FIRST-LINE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

  • MERCK - INDEPENDENT DATA MONITORING COMMITTEE CONCLUDED TRIAL MET PRIMARY ENDPOINT OF RPFS IN MEN WITH MCRPC WHO HAD NOT RECEIVED TREATMENT IN FIRST-LINE SETTING

  • MERCK & CO INC - SAFETY AND TOLERABILITY WERE CONSISTENT WITH KNOWN PROFILES OF EACH MEDICINE IN PHASE 3 PROPEL TRIAL

  • MERCK & CO INC - PHASE 3 PROPEL TRIAL OS DATA ARE STILL IMMATURE, AND TRIAL WILL CONTINUE TO ASSESS OS AS A KEY SECONDARY ENDPOINT

Source text for Eikon: ID:nBw4ZcJBWa

Further company coverage: MRK


((Reuters.Briefs@thomsonreuters.com;))